HRP20180324T1 - Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala - Google Patents

Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala Download PDF

Info

Publication number
HRP20180324T1
HRP20180324T1 HRP20180324TT HRP20180324T HRP20180324T1 HR P20180324 T1 HRP20180324 T1 HR P20180324T1 HR P20180324T T HRP20180324T T HR P20180324TT HR P20180324 T HRP20180324 T HR P20180324T HR P20180324 T1 HRP20180324 T1 HR P20180324T1
Authority
HR
Croatia
Prior art keywords
ethylamino
alkyl
compound
hydrogen
butoxyphenyl
Prior art date
Application number
HRP20180324TT
Other languages
English (en)
Inventor
Piero Melloni
Alessandra Restivo
Emanuela Izzo
Simona Francisconi
Elena Colombo
Cibele Sabido-David
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of HRP20180324T1 publication Critical patent/HRP20180324T1/hr
Publication of HRP20180324T8 publication Critical patent/HRP20180324T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (34)

1. Spoj opće formule (I): [image] (I) u kojoj: X je -O-, -S- ili -SO2-; Y je vodik, OH ili O(C1-C4)alkil; Z je =O ili =S; R je (C3-C10)alkil; ω-trifluor(C3-C10)alkil; R1 i R2 jesu, neovisno, vodik, hidroksi, (C1-C8)alkoksi, (C1-C8)alkiltio, halogen, trifluormetil ili 2,2,2-trifluoretil; ili jedan od R1 i R2 je u ortho-položaju prema R-X- i, uzet zajedno s istim R-X-, predstavlja skupinu [image] u kojoj R0 jest (C2-C9)alkil; R3 i R’3 jesu, neovisno, vodik ili (C1-C4)alkil; R4 i R5 jesu, neovisno, vodik, (C1-C4)alkil; ili R4 je vodik te R5 je skupina odabrana od -CH2-OH, -CH2-O-(C1-C6)alkil, -CH(CH3)-OH, -(CH2)2-S-CH3, benzil i 4-hidroksibenzil; ili R4 i R5, uzeti zajedno sa susjednim ugljikovim atomom, tvore (C3-C6)cikloalkilni ostatak; R6 i R7 jesu neovisno vodik ili (C1-C6)alkil; ili uzeti zajedno sa susjednim dušikovim atomom tvore peteročlani ili šesteročlani monociklički zasićeni heterociklički prsten, koji može sadržavati jedan dodatni heteroatom odabran od -O-, -S- i -NR8- gdje R8 je vodik ili (C1-C6)alkil; pod uvjetom da kada X jest -S- ili -SO2-, tada Y nije OH ili O(C1-C4)alkil; u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli.
2. Spoj iz patentnog zahtjeva 1 naznačeno time da: X je -O-, -S-; Y je vodik, OH ili O(C1-C3)alkil; Z je =O ili =S; R je (C4-C7)alkil ili ω-trifluor(C4-C6)alkil; R1 i R2 jesu, neovisno, vodik, (C1-C4)alkoksi, halogen, trifluormetil ili 2,2,2-trifluoretil; ili jedan od R1 i R2 je u ortho-položaju prema R-X- i, uzet zajedno s istim R-X-, predstavlja skupinu [image] u kojoj R0 jest (C2-C5)alkil; R3 i R’3 jesu, neovisno, vodik ili (C1-C3)alkil; R4 i R5 jesu, neovisno, vodik ili (C1-C4)alkil; ili R4 je vodik te R5 je skupina odabrana od -CH2-OH, -CH2-O-(C1-C3)alkil, -(CH2)2-S-CH3, benzil i 4-hidroksibenzil; R6 i R7 jesu, neovisno, vodik ili (C1-C4)alkil; ili uzeti zajedno sa susjednim dušikovim atomom tvore peteročlani ili šesteročlani monociklički zasićeni heterociklički prsten, koji može sadržavati jedan dodatni heteroatom odabran od -O- i -NR8- gdje R8 je vodik ili (C1-C3)alkil; pod uvjetom da kada X jest -S-, tada Y nije OH ili O(C1-C3)alkil; u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli.
3. Spoj iz patentnog zahtjeva 1 naznačeno time da: X je -O-, -S-; Y je vodik ili O(C1-C3)alkil; Z je =O ili =S; R je (C4-C7)alkil ili ω-trifluor(C4-C6)alkil; R1 i R2 jesu, neovisno, vodik, (C1-C3)alkoksi, fluor, klor, trifluormetil ili 2,2,2-trifluoretil; ili jedan od R1 i R2 je u ortho-položaju prema R-X- i uzet zajedno s istim R-X-, predstavlja skupinu [image] u kojoj R0 jest (C3-C4)alkil; R3 i R’3 jesu, neovisno, vodik ili (C1-C3)alkil; R4 i R5 jesu, neovisno, vodik ili (C1-C4)alkil; ili R4 je vodik te R5 je skupina odabrana od -CH2-OH, -CH2-O-(C1-C3)alkil, benzil i 4-hidroksibenzil; R6 i R7 jesu, neovisno, vodik ili (C1-C3)alkil; ili uzeti zajedno sa susjednim dušikovim atomom tvore peteročlani ili šesteročlani monociklički zasićeni heterociklički prsten, koji može sadržavati jedan dodatni heteroatom odabran od -O- i -NR8-, gdje R8 je vodik ili (C1-C3)alkil; pod uvjetom da kada X jest -S-, tada Y nije O(C1-C3)alkil; u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli.
4. Spoj iz patentnog zahtjeva 1 naznačeno time da: X je -O-; Y je vodik; Z je =O; R je (C4-C6)alkil; R1 i R2 jesu, neovisno, vodik ili halogen, preferirano fluor; R3, R’3, R4 i R5 su vodik; R6 i R7 jesu, neovisno, vodik ili (C1-C3)alkil; u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli.
5. Spoj iz patentnog zahtjeva 1 naznačeno time da je odabran od: 2-[2-(3-butoksifenil)-etilamino]-acetamid 2-[2-(3-pentiloksifenil)-etilamino]-acetamid 2-[2-(3-heksiloksifenil)-etilamino]-acetamid 2-[2-(3-butoksifenil)-etilamino]-N-metilacetamid 2-[2-(3-pentiloksifenil)-etilamino]-N-metilacetamid 2-[2-(3-heksiloksifenil)-etilamino]-N-metilacetamid 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butilsulfonilfenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-(N’-hidroksi)etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-(N’-metoksi)etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-(N’-propoksi)etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetil-tioacetamid 2-[2-(3-butoksifenil)-2-metilpropilamino]-N,N-dimetilacetamid 2-{2-[3-(4,4,4-trifluorbutoksi)fenil]-etilamino}-N,N-dimetilacetamid 2-[2-(3-butiltiofenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksi-2-klorfenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksi-2-fluorfenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksi-4-metoksifenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-etilamino]-N,N-dietilacetamid 2-[2-(3-butoksifenil)-etilamino]-N,N-dipropilacetamid 2-[2-(3-butoksifenil)-etilamino]-N,N-dibutilacetamid 2-[2-(3-pentiloksifenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-heksiloksifenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksifenil)-etilamino]-1-pirolidin-1-il-etan-1-on 2-[2-(3-pentiloksifenil)-etilamino]-1-pirolidin-1-il-etan-1-on 2-[2-(3-heksiloksifenil)-etilamino]-1-pirolidin-1-il-etan-1-on 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilpropanamid 2-[2-(3-butoksifenil)-etilamino]-3-hidroksi-N,N-dimetilpropanamid 2-[2-(3-butoksifenil)-etilamino]-3-metoksi-N,N-dimetilpropanamid 2-[2-(3-butoksifenil)-etilamino]-3-propoksi-N,N-dimetilpropanamid 2-[2-(3-butoksifenil)-etilamino]-2,N,N-trimetilpropanamid 2-[2-(3-pentiloksifenil)-etilamino]-2,N,N-trimetilpropanamid 2-[2-(3-heksiloksifenil)-etilamino]-2,N,N-trimetilpropanamid (S)-2-[2-(3-butoksifenil)-etilamino]-propanamid (S)-2-[2-(3-butoksifenil)-etilamino]-N-metilpropanamid (S)-2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilpropanamid (R)-2-[2-(3-butoksifenil)-etilamino]-propanamid (R)-2-[2-(3-butoksifenil)-etilamino]-N-metilpropanamid (R)-2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilpropanamid 2-[2-(3-butoksi-2-trifluormetilfenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksi-4-trifluormetilfenil)-etilamino]-N,N-dimetilacetamid 2-[2-(3-butoksi-5-trifluormetilfenil)-etilamino]-N,N-dimetilacetamid u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli, preferirano njegova sol s klorovodičnom ili metansulfonskom kiselinom.
6. Spoj iz patentnog zahtjeva 1 naznačeno time da je 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilacetamid, 2-[2-(3-butoksi-2,6-difluorfenil)-etilamino]-N,N-dimetilacetamid, 2-[2-(3-pentiloksifenil)-etilamino]-N,N-dimetilacetamid, ili 2-[2-(3-heksiloksifenil)-etilamino]-N,N-dimetilacetamid, i njihove farmaceutski prihvatljive soli.
7. Spoj iz patentnog zahtjeva 6 naznačeno time da je 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilacetamid ili njegova farmaceutski prihvatljiva sol.
8. Spoj iz bilo kojeg od patentnih zahtjeva 6 i 7 naznačeno time da farmaceutski prihvatljiva sol jest hidroklorid ili metansulfonat.
9. Spoj iz patentnog zahtjeva 1 naznačeno time da: X je -SO2-; ili Y je OH ili O(C1-C4)alkil; ili Z je =S; ili R je (C9-C10)alkil ili ω-trifluor(C3-C10)alkil; ili R1 i/ili R2 su različiti od vodika; ili oba R3 i R'3 su različiti od vodika; ili oba R4 i R5 su različiti od vodika, ali kad su uzeti zajedno sa susjednim ugljikovim atomom ne tvore (C3-C6)cikloalkilni ostatak; ili R6 i R7, uzeti zajedno sa susjednim dušikovim atomom tvore monociklički peteročlani ili šesteročlani zasićeni heterociklički prsten, koji može sadržavati jedan dodatni heteroatom odabran od -O-, -S- i -NR8-, gdje R8 je vodik ili (C1-C6)alkil; pod uvjetom da kada X jest -S- ili -SO2-, tada Y nije OH ili O(C1-C4)alkil; u kojem slučaju, može biti jedan optički izomer u izoliranom obliku ili njegova smjesa u bilo kojem omjeru i njegove farmaceutski prihvatljive soli.
10. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu kao lijek.
11. Spoj iz patentnog zahtjeva 1 za upotrebu kao lijek aktivan kao modulator natrijevih i/ili kalcijevih kanala za liječenje patologija u kojima gore rečeni mehanizam (mehanzimi) igra (igraju) patološku ulogu, koja je neurološki, kognitivni, psihijatrijski, upalni, urogenitalni ili gastrointestinalni poremećaj, a rečeni lijek uopće nema MAO inhibitorsku aktivnost ili ima znatno smanjenu MAO inhibitorsku aktivnost.
12. Spoj iz bilo kojeg od patentnih zahtjeva 2, 3 i 4 za upotrebu prema patentnom zahtjevu 11.
13. Spoj iz patentnog zahtjeva 5 za upotrebu prema patentnom zahtjevu 11.
14. Spoj iz patetnog zahtjeva 6 za upotrebu prema patentnom zahtjevu 11.
15. Spoj iz patentnog zahtjeva 7 za upotrebu prema patentnom zahtjevu 11.
16. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest neurološki poremećaj odabran od boli i migrene.
17. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 16 pri čemu bol jest sindrom neuropatske boli ili sindrom upalne boli.
18. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 16 pri čemu bol jest akutna ili kronična bol.
19. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest neurološki poremećaj odabran od Alzheimerove bolesti, Parkinsonove bolesti, epilepsije, sindroma nemirnih nogu, moždanog udara ili cerebralne ishemije.
20. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest upalni proces koji djeluje na sve sustave tijela odabran od artritičnog stanja, poremećaja koji djeluje na kožu i pripadajuća tkiva, poremećaja respiratornog sustava ili poremećaja imunološkog i endokrinološkog sustava.
21. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest kognitivni i/ili psihijatrijski poremećaj odabran od blagog kognitivnog oštećenja, depresije, bipolarnog poremećaja, manije, shizofrenije, psihoze, anksioznosti i ovisnosti.
22. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest urogenitalni poremećaj.
23. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 11, pri čemu poremećaj jest gastrointestinalni poremećaj.
24. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema bilo kojem od patentnih zahtjeva 11 i 16 do 23, pri čemu je rečeni spoj kombiniran s jednim ili više drugih terapeutskih sredstava.
25. Farmaceutski pripravak koji sadrži, kao aktivnu tvar, spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 zajedno s farmaceutski prihvatljivim terapeutski inertnim organskim ili anorganskim materijalima za nosač.
26. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 21, pri čemu je rečeni spoj kombiniran s jednim ili više drugih terapeutskih sredstava prema patentnom zahtjevu 24, pri čemu je drugo terapeutsko sredstvo tipično ili atipično antipsihotičko sredstvo.
27. Spoj iz patentnog zahtjeva 26 naznačeno time da tipično antipsihotičko sredstvo jest haloperidol, a atipično antipsihotičko sredstvo odabrano je od risperidona i klozapina.
28. Spoj iz patentnog zahtjeva 26, naznačeno time da rečeni spoj jest 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilacetamid ili njegova farmaceutski prihvatljiva sol, tipično antipsihotičko sredstvo jest haloperidol, a atipično antipsihotičko sredstvo odabrano je od risperidona i klozapina.
29. Spoj iz patentnog zahtjeva 26, naznačeno time da rečeni spoj jest hidroklorid ili metansulfonat 2-[2-(3-butoksifenil)-etilamino]-N,N-dimetilacetamida te tipično antipsihotičko sredstvo jest haloperidol, a atipično antipsihotičko sredstvo odabrano je od risperidona i klozapina.
30. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 20, pri čemu poremećaj jest poremećaj imunološkog sustava.
31. Spoj iz patentnog zahtjeva 30, naznačeno time da poremećaj imunološkog sustava jest multipla skleroza ili drugi demijelinizirajući poremećaji.
32. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema bilo kojem od patentnih zahtjeva 11 do 24 i 26 do 31 gdje su pacijenti koji pate od poremećaja (poremećaja) posebno osjetljivi na neželjene nuspojave zbog MAO inhibitorske aktivnosti.
33. Upotreba spoja iz bilo kojeg od patentnih zahtjeva 1 do 9 za pripravu lijeka aktivnog kao modulator natrijevog i/ili kalcijevog kanala za liječenje patologija u kojima gore rečeni mehanizam (mehanizimi) igra (igraju) patološku ulogu, koja je neurološki, kognitivni, psihijatrijski, upalni, urogenitalni ili gastrointestinalni poremećaj, a rečeni lijek uopće nema MAO inhibitorsku aktivnost ili ima znatno smanjenu MAO inhibitorsku aktivnost.
34. Upotreba prema patentnom zahtjevu 33 pri čemu poremećaj jest kao u bilo kojem od patentnih zahtjeva 16 do 23.
HRP20180324TT 2007-06-15 2018-02-22 Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala HRP20180324T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07011766 2007-06-15
PCT/EP2008/003848 WO2008151702A1 (en) 2007-06-15 2008-05-14 Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
EP08749449.8A EP2155663B1 (en) 2007-06-15 2008-05-14 Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Publications (2)

Publication Number Publication Date
HRP20180324T1 true HRP20180324T1 (hr) 2018-04-06
HRP20180324T8 HRP20180324T8 (hr) 2019-03-08

Family

ID=38658156

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180324TT HRP20180324T8 (hr) 2007-06-15 2018-02-22 Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala

Country Status (28)

Country Link
US (8) US8519000B2 (hr)
EP (1) EP2155663B1 (hr)
JP (1) JP5440496B2 (hr)
KR (1) KR101545124B1 (hr)
CN (1) CN101687773B (hr)
AR (1) AR068976A1 (hr)
AU (1) AU2008261325B2 (hr)
BR (1) BRPI0813363B8 (hr)
CA (1) CA2689561C (hr)
CY (1) CY1119787T1 (hr)
DK (1) DK2155663T3 (hr)
EA (1) EA018195B1 (hr)
ES (1) ES2655704T3 (hr)
HK (1) HK1138566A1 (hr)
HR (1) HRP20180324T8 (hr)
HU (1) HUE038113T2 (hr)
IL (1) IL202235A (hr)
LT (1) LT2155663T (hr)
MX (1) MX2009013119A (hr)
NO (1) NO2155663T3 (hr)
NZ (1) NZ581288A (hr)
PL (1) PL2155663T3 (hr)
PT (1) PT2155663T (hr)
RS (1) RS56780B1 (hr)
SI (1) SI2155663T1 (hr)
TR (1) TR201802576T4 (hr)
TW (1) TWI400071B (hr)
WO (1) WO2008151702A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
JP5213265B2 (ja) * 2009-10-08 2013-06-19 花王株式会社 Ｌｏｘ−１発現調節剤の評価又は選択方法
PL2723710T3 (pl) * 2011-06-27 2017-02-28 Newron Pharmaceuticals S.P.A. Fluorowane pochodne aryloalkiloaminokarboksyamidowe
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CA3004448A1 (en) * 2015-11-12 2017-05-18 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
CN106316824B (zh) * 2016-08-18 2018-10-19 广州康瑞泰药业有限公司 一种合成2-氟环丙烷甲酸的新方法
CN112041296B (zh) * 2018-04-28 2023-12-29 上海璃道医药科技有限公司 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途
DE112019004296T5 (de) * 2018-08-30 2021-07-22 Sabic Global Technologies B.V. Aromatisierungskatalysator mit verbesserter isomerisierung, herstellungsverfahren und verwendung davon
EP3725769A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB586645A (en) * 1944-07-19 1947-03-26 Burroughs Wellcome Co Improvements relating to the synthesis of amino acid derivatives and salts thereof
GB1254332A (en) * 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5051403A (en) 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
CA2151741C (en) 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
GB9500691D0 (en) 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
US5845454A (en) * 1996-04-23 1998-12-08 Malizia; John T. Drop ceiling hanging system
EP0910565A1 (en) 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
WO1998054123A1 (en) 1997-05-30 1998-12-03 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
DE19740110A1 (de) 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6458781B1 (en) 1998-04-27 2002-10-01 David Thomas Connor Substituted diarylalkyl amides as calcium channel antagonists
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
WO2000006559A1 (en) 1998-07-30 2000-02-10 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6472530B1 (en) 1999-09-22 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
CA2403808A1 (en) 2000-03-23 2001-09-27 Ortho-Mcneil Pharmaceutical, Inc. Thiepino [3,2-b] dihydropyridines and related compositions and methods
BR0109706A (pt) 2000-03-31 2003-02-04 Euro Celtique Sa Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
SE0102858D0 (sv) 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
AU2002333374B2 (en) 2001-09-03 2007-03-22 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
SI1458386T1 (sl) 2001-12-27 2007-08-31 Ortho Mcneil Pharm Inc Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
WO2004087125A1 (en) * 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Amino acid derivatives as inhibitors of mammalian sodium channels
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ES2347581T3 (es) 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
RS54522B1 (en) * 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Also Published As

Publication number Publication date
CN101687773A (zh) 2010-03-31
US9585869B2 (en) 2017-03-07
US20150157602A1 (en) 2015-06-11
US20150157598A1 (en) 2015-06-11
US20150157600A1 (en) 2015-06-11
EA018195B1 (ru) 2013-06-28
CA2689561A1 (en) 2008-12-18
EA201070018A1 (ru) 2010-08-30
BRPI0813363A2 (pt) 2014-12-30
BRPI0813363B1 (pt) 2019-11-12
US9248116B2 (en) 2016-02-02
ES2655704T3 (es) 2018-02-21
AU2008261325B2 (en) 2012-12-06
US20130289122A1 (en) 2013-10-31
WO2008151702A1 (en) 2008-12-18
US9474738B2 (en) 2016-10-25
JP5440496B2 (ja) 2014-03-12
HRP20180324T8 (hr) 2019-03-08
US9603832B2 (en) 2017-03-28
PT2155663T (pt) 2018-01-16
KR20100039848A (ko) 2010-04-16
US9474737B2 (en) 2016-10-25
PL2155663T3 (pl) 2018-06-29
US8519000B2 (en) 2013-08-27
US20100210631A1 (en) 2010-08-19
AU2008261325A2 (en) 2010-04-08
DK2155663T3 (en) 2018-01-22
US9474739B2 (en) 2016-10-25
MX2009013119A (es) 2010-03-04
US20150157599A1 (en) 2015-06-11
AR068976A1 (es) 2009-12-23
US9051240B2 (en) 2015-06-09
SI2155663T1 (en) 2018-03-30
BRPI0813363B8 (pt) 2021-05-25
HUE038113T2 (hu) 2018-09-28
TW200908956A (en) 2009-03-01
AU2008261325A1 (en) 2008-12-18
IL202235A0 (en) 2010-06-16
TWI400071B (zh) 2013-07-01
IL202235A (en) 2015-03-31
CN101687773B (zh) 2014-07-30
JP2010529969A (ja) 2010-09-02
EP2155663A1 (en) 2010-02-24
LT2155663T (lt) 2018-02-12
EP2155663B1 (en) 2017-11-29
NZ581288A (en) 2011-08-26
TR201802576T4 (tr) 2018-03-21
HK1138566A1 (en) 2010-08-27
RS56780B1 (sr) 2018-04-30
CY1119787T1 (el) 2018-06-27
NO2155663T3 (hr) 2018-04-28
CA2689561C (en) 2015-11-17
US20150157601A1 (en) 2015-06-11
US20130274249A1 (en) 2013-10-17
KR101545124B1 (ko) 2015-08-18

Similar Documents

Publication Publication Date Title
HRP20180324T1 (hr) Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala
JP2010529969A5 (hr)
JP2022516575A (ja) ケタミン誘導体およびその組成物
WO2017049177A1 (en) Farnesoid x receptor agonists and uses thereof
NO341215B1 (no) Forbindelser og sammensetninger som pinnsvin reaksjonsvei modulatorer
WO2017049172A1 (en) Farnesoid x receptor agonists and uses thereof
HRP20160005T1 (hr) 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala
AU2017361253A1 (en) MAGL inhibitors
HRP20161412T1 (hr) Fluorirani derivati arilalkilaminokarboksamida
BR112015014097A2 (pt) compostos químicos
TW201623257A (zh) 藥理活性之喹唑啉二酮衍生物
TWI441631B (zh) 有效於治療精神障礙之α－胺基醯胺衍生物
KR20180100627A (ko) 섬망의 예방 또는 치료제
JP2018523644A (ja) アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用
WO2023115167A1 (en) Compounds
JP7167235B2 (ja) 自閉症スペクトラム障害の予防または治療剤
ES2770128T3 (es) Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
US20180127466A1 (en) Nmda receptor modulators and prodrugs, salts, and uses thereof
US11434244B2 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
KR102471059B1 (ko) 장애의 치료를 위한 하이드록시노르케타민 유도체
WO2019152688A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2014152869A2 (en) Benzyl urea derivatives for activating tgf-beta signaling
WO2012101058A1 (en) 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
JP7430175B2 (ja) オキサジアゾールを含む化合物及びそれを含む医薬組成物
RU2789456C2 (ru) Соединение, содержащее оксадиазол, и содержащая его фармацевтическая композиция